BioClinica[TM] Acquires CardioNow from Agfa Healthcare.-Adds Proven Solution for Secure, Regulatory Compliant Electronic Transmission and Analysis of Medical Images for Clinical Trials- NEWTOWN, Pa. -- BioClinica, Inc., (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BIOC BIOC Biocontrol (pest control without chemicals) BIOC Break Into Other Computers BIOC Buyer In Ordinary Course (legal) BIOC Basic Identity Object Class BIOC Biometric Characteristics ), a global provider of clinical trial services, today announced that it has acquired the CardioNow unit of Agfa HealthCare. With this addition, BioClinica now offers streamlined electronic transport solutions to facilitate the blinding, sharing, tracking and archiving of medical images for multi-center clinical trials as part of its suite of imaging services. Imaging information will also be integrated with BioClinica Express electronic data capture to further simplify and enhance the clinical trial process for life science companies. Since 1999, CardioNow has provided core labs, investigator sites, and medical device and pharmaceutical companies with an established and proven web-based system for the secure, regulatory compliant transmission and analysis of medical images that are integral components of clinical trials. The solution is also extensively utilized by remote independent reviewers for online case review and quantitative analysis Quantitative Analysis A security analysis that uses financial information derived from company annual reports and income statements to evaluate an investment decision. Notes: , clinical event adjudication The legal process of resolving a dispute. The formal giving or pronouncing of a judgment or decree in a court proceeding; also the judgment or decision given. The entry of a decree by a court in respect to the parties in a case. , and data safety monitoring Safety Monitoring of a clinical trial is conducted by an independent physician with relevant expertise. This is accomplished by review of adverse event, immediately after they occur, with timely follow-up through resolution. . Over the past 10 years, CardioNow has successfully managed more than 8.8 million DICOM (medical, standard) DICOM - (From Digital Imaging and COmmunications in Medicine) A standard developed by ACR-NEMA (American College of Radiology - National Electrical Manufacturer's Association) for communications between medical imaging devices. (Digital Imaging and Communications in Medicine Digital Imaging and Communications in Medicine (DICOM) is a standard for handling, storing, printing, and transmitting information in medical imaging. It includes a file format definition and a network communications protocol. ) images for clinical studies worldwide. With the integration of CardioNow, BioClinica will be able to manage every step of the process that begins once a medical image is acquired at a clinical site through the delivery of evaluated results to the sponsor. This end-to-end control will ensure that the process is as efficient and expedient ex·pe·di·ent adj. 1. Appropriate to a purpose. 2. a. Serving to promote one's interest: was merciful only when mercy was expedient. b. as possible. "CardioNow fits perfectly into BioClinica's strategy of adding components that are both complimentary to our current products and services and that help to create a more efficient clinical trial process. We will continue to build on the superior technology and high level of customer service offered by Agfa Healthcare's CardioNow unit," said Mark Weinstein, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of BioClinica. "An additional benefit is that once CardioNow is integrated with our current processes -- approximately 45 days -- we can offer our clients an immediate cost savings on each of the more than 200 clinical trials that we are currently supporting." "A leading solution like CardioNow is well suited to support the ongoing expansion of BioClinica's extensive global clinical trial services portfolio," said Eric Maurincomme, Chief Strategy & Marketing Officer of Agfa HealthCare. "We are convinced that the CardioNow business will continue to flourish within BioClinica, and are working closely together to enable a smooth transition." Mr. Weinstein concluded, "CardioNow will provide immediate benefits to our Bioimaging Services clients and as such the CardioNow team will be integrated into that division and report to Dave Pitler, president of our Bio-Imaging Services division. We will immediately begin work on integrating the CardioNow products and services with our eclinical offering to provide medical device and pharmaceutical clients with a comprehensive offering that will be unmatched in the industry." About BioClinica, Inc. BioClinica, Inc. is a leading global provider of clinical trials services, helping to support drug and product development efforts through all phases of the clinical trial process. Created from the acquisition of Phoenix Data Systems, Inc. by Bio-Imaging Technologies, Inc., BioClinica offers industry-leading medical image management and best-of-breed electronic data capture to companies in the life sciences industry. In addition, BioClinica offers solutions that combine these core services The introduction to this article provides insufficient context for those unfamiliar with the subject matter. Please help [ improve the introduction] to meet Wikipedia's layout standards. You can discuss the issue on the talk page. to maximize efficiency and manageability throughout the entire clinical development process. With more than 2,000 successful trials, BioClinica is unsurpassed in its knowledge and experience, helping bring many of today's drugs from early phase development through final approval. BioClinica operates two state-of-the-art, FDA-compliant core labs in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and Europe, with business offices in the United States, France, Germany, United Kingdom and the Netherlands. For more information, please visit www.bioclinica.com. About Agfa Healthcare Agfa HealthCare, a member of the Agfa-Gevaert Group, is a leading provider of IT-enabled clinical workflow and diagnostic image management solutions, and state-of-the-art systems for capturing and processing images in hospitals and healthcare facilities. Agfa HealthCare has over a century of healthcare experience related to diagnostic imaging and has been a pioneer in the healthcare IT market since the early 1990's. The business group has sales offices and agents in over 100 markets worldwide. Sales for Agfa HealthCare in 2008 were 1,223 million Euro. For more information, please visit www.agfahealthcare.com . Certain matters discussed in this press release are "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " intended to qualify for the safe harbors Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. from liability established by the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and the recent Form 10-Q Form 10-Q See 10-Q. . |
|
|||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion